NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Show more
Location: Gooimeer 2-35, Naarden, 1411 DC, Netherlands | Website: https://www.newamsterdampharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
0.00
52 Wk Range
$5.45 - $16.75
Previous Close
$8.00
Open
$8.00
Volume
N/A
Day Range
$8.00 - $8.00
Enterprise Value
0.00
Cash
808.5M
Avg Qtr Burn
-35.11M
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|